BRCA1 and lung carcinoma: In fact, we identified several lung cancer WGS cases with high HRD-induced mutational signatures that were not associated with BRCA1/2 mutations and those could also be responding to PARP inhibitor therapy as our cell line-based preclinical analysis suggests.